MRK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Merck & Co Inc (MRK) is not a strong buy at the moment for a beginner, long-term investor. While the company has positive catalysts such as its AI partnership with Google Cloud and strong interest in new therapies, the technical indicators show a neutral to bearish trend, and the financial performance in the latest quarter reflects declining net income, EPS, and gross margin. Additionally, insider selling has significantly increased, which is a negative signal. Given the investor's preference for long-term investments, it would be prudent to wait for a more favorable entry point or stronger signals of growth.
The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 39.797, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 112.839), but the overall technical indicators suggest caution.
Partnership with Google Cloud for a $1 billion AI-driven initiative to enhance operational efficiency and drug development.
Strong interest in new therapies, including a potential $8 billion cancer drug deal with Inhibrx.
Significant insider selling, with a 2945.40% increase in the last month.
Declining financial performance in Q4 2025, including a 20.84% drop in net income and a 19.59% drop in EPS.
In Q4 2025, revenue increased by 4.97% YoY to $16.4 billion. However, net income dropped by 20.84% YoY to $2.96 billion, EPS decreased by 19.59% YoY to $1.19, and gross margin declined by 2.78% to 74.15%.
Analysts are generally bullish on Merck, with multiple firms raising price targets and maintaining Buy or Overweight ratings. The price targets range from $125 to $150, reflecting optimism about the company's pipeline, upcoming launches, and ability to navigate Keytruda's patent cliff.
